Short answer
Exelixis Inc (EXEL) filed its Q2 2019 10-Q quarterly report on Jul 31, 2019 for the quarter ended Jun 28, 2019.
Exelixis Inc Q2 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $240.3M, up from $186.1M YoY, 29.1% increase
- Net income $79.0M vs $87.5M YoY, effective tax rate 20.8% vs 1.0%
- Best performer CABOMETYX revenue $189.0M vs $141.1M; COMETRIQ $4.7M vs $4.7M
- Cash and investments $1,161.0M vs $851.6M; operating cash flow $293.3M vs $146.3M
- Near-term outlook: continued significant cabozantinib spending, competition, reimbursement pressure and rising discounts and allowances
Risk Factors
- No material changes from the 2018 10-K, with Brexit uncertainty updated after the UK departure date moved to October 31, 2019
- Regulatory risk: March 2019 Senate Finance Committee inquiry increased scrutiny of pharmaceutical patient-assistance foundations
- Operational risk: UK contract-manufacturing facilities support EU packaging, labeling, storage and distribution
- Financial risk: cash and investments increased to $1,161.0 million at June 30, 2019 from $851.6 million at December 31, 2018
- Market risk: ICI-based oncology combinations intensify competition in CABOMETYX indications
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Exelixis Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.